|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111.38 USD | -0.02% |
|
+6.77% | +10.39% |
| 01-14 | UBS Lowers Price Target on Clorox to $115 From $119, Maintains Neutral Rating | MT |
| 01-13 | The Clorox Company Introduces Clorox PURE Allergen Neutralizer | CI |
| Capitalization | 13.59B 11.66B 10.86B 10.1B 18.86B 1,227B 20.33B 125B 49.11B 587B 50.97B 49.92B 2,150B | P/E ratio 2026 * |
19.5x | P/E ratio 2027 * | 17.3x |
|---|---|---|---|---|---|
| Enterprise value | 16.62B 14.26B 13.28B 12.36B 23.06B 1,501B 24.86B 153B 60.07B 718B 62.34B 61.05B 2,630B | EV / Sales 2026 * |
2.56x | EV / Sales 2027 * | 2.45x |
| Free-Float |
94.01% | Yield 2026 * |
4.43% | Yield 2027 * | 4.64% |
Last Transcript: The Clorox Company
| 1 day | +0.05% | ||
| 1 week | +6.77% | ||
| Current month | +10.39% | ||
| 1 month | +9.42% | ||
| 3 months | -5.96% | ||
| 6 months | -10.36% | ||
| Current year | +10.39% |
| 1 week | 103.26 |  | 111.52 |
| 1 month | 96.66 | | 111.52 |
| Current year | 98.75 | | 111.52 |
| 1 year | 96.66 | | 164.22 |
| 3 years | 96.66 | | 178.2 |
| 5 years | 96.66 | | 231.11 |
| 10 years | 96.66 | | 239.87 |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Rendle
CEO | Chief Executive Officer | 48 | 14/09/2020 |
Luc Bellet
DFI | Director of Finance/CFO | 48 | 01/04/2025 |
Chau Banks
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/06/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Esther Lee
BRD | Director/Board Member | 67 | 19/08/2013 |
| Director/Board Member | 68 | 01/07/2015 | |
Allan Mackay
BRD | Director/Board Member | 71 | 15/08/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.02% | +6.77% | -29.69% | -24.79% | 13.59B | |
| -0.15% | 0.00% | +27.98% | +2.97% | 55.9B | |
| -0.32% | +4.36% | -13.38% | +5.76% | 21.65B | |
| -5.04% | -5.77% | +40.40% | -48.85% | 5.81B | |
| +0.29% | +3.66% | -8.14% | -18.71% | 5.12B | |
| +0.90% | +0.60% | +2.42% | +18.15% | 2.9B | |
| +0.43% | +1.43% | -10.02% | +18.19% | 2.75B | |
| +1.94% | -0.82% | +21.67% | +76.79% | 1.49B | |
| -1.44% | -7.16% | -34.42% | +26.75% | 1.04B | |
| +3.34% | +12.48% | +30.00% | +230.27% | 904M | |
| Average | -0.00% | +2.01% | +2.68% | +28.65% | 11.12B | |
| Weighted average by Cap. | -0.33% | +3.64% | +9.60% | +0.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.49B 5.57B 5.19B 4.83B 9.01B 586B 9.71B 59.63B 23.46B 280B 24.35B 23.85B 1,027B | 6.8B 5.83B 5.43B 5.05B 9.43B 614B 10.17B 62.45B 24.57B 294B 25.5B 24.97B 1,076B |
| Net income | 705M 605M 564M 524M 979M 63.67B 1.05B 6.48B 2.55B 30.46B 2.65B 2.59B 112B | 799M 685M 638M 594M 1.11B 72.1B 1.19B 7.34B 2.89B 34.49B 3B 2.93B 126B |
| Net Debt | 3.03B 2.6B 2.42B 2.25B 4.21B 274B 4.53B 27.85B 10.96B 131B 11.37B 11.14B 480B | 3.05B 2.62B 2.44B 2.27B 4.23B 275B 4.56B 28B 11.02B 132B 11.43B 11.2B 482B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 111.30 $ | -0.09% | 270,646 |
| 14/01/26 | 111.41 $ | +2.34% | 2,152,488 |
| 13/01/26 | 108.86 $ | +1.76% | 1,785,683 |
| 12/01/26 | 106.98 $ | +0.74% | 2,243,458 |
| 09/01/26 | 106.19 $ | +1.86% | 1,901,513 |
Delayed Quote Nyse, January 15, 2026 at 07:26 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CLX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition